- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04323488
Neural Mechanisms of Successful Intervention in Children With Dyslexia
August 9, 2021 updated by: Jason Yeatman, Stanford University
Dyslexia, an impairment in accurate or fluent word recognition, is the most common learning disability affecting roughly ten percent of children.
This proposal capitalizes on cutting edge neuroimaging methods, in combination with reading education programs, to generate a new understanding of how successful reading education shapes the development of the brain circuits that support skilled reading.
A deeper understanding of the mechanisms of successful remediation of dyslexia, and individual differences in learning, will pave the way for personalized approaches to dyslexia treatment.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years to 12 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Reading difficulties defined as low scores on standardized measures of reading skills
Exclusion Criteria:
- no major contraindication for MRI (braces, metal implants, pacemakers, vascular stents, or metallic ear tubes).
- Because the study involves measurements of reading and language ability, new recruits will be native English speakers.
- Subjects have no history of neurological disorder, significant psychiatric problems
- exclude claustrophobic subjects since an MRI might be uncomfortable for them.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lindamood-Bell Seeing Stars
Subjects receive reading instruction focusing on the building blocks of reading
|
Seeing Stars in a curriculum developed by Lindamood-Bell.
It is published and openly available.
It involves systematic training in the building blocks of skilled reading.
|
No Intervention: Control
Subjects are followed longitudinally but do not receive intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
White matter plasticity
Time Frame: Change between baseline (within 2 weeks pre-intervention) and post-intervention (within 2 weeks post-intervention)
|
Change in white matter mean diffusivity measured with diffusion MRI
|
Change between baseline (within 2 weeks pre-intervention) and post-intervention (within 2 weeks post-intervention)
|
White matter plasticity
Time Frame: Change between baseline (within 2 weeks pre-intervention) and post-intervention (1 year follow-up)
|
Change in white matter mean diffusivity measured with diffusion MRI
|
Change between baseline (within 2 weeks pre-intervention) and post-intervention (1 year follow-up)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2021
Primary Completion (Anticipated)
June 30, 2024
Study Completion (Anticipated)
June 30, 2024
Study Registration Dates
First Submitted
March 23, 2020
First Submitted That Met QC Criteria
March 24, 2020
First Posted (Actual)
March 26, 2020
Study Record Updates
Last Update Posted (Actual)
August 12, 2021
Last Update Submitted That Met QC Criteria
August 9, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 52231
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
IPD Plan Description
All consent forms in the Yeatman lab contain a data sharing clause that allows de-identified data to be shared publicly.
The lab policy is that data and analysis code are always publicly released to accompany each published manuscript from the lab.
This policy ensures that published findings can be reproduced by other researchers and the general public.
In our experience, this also creates a useful resource to document our methods, describe methodological decisions in greater detail than afforded by journal articles, and publicly release datasets that may be of utility to other researchers.
Data and code are organized into a well-documented repository (see https://github.com/yeatmanlab) with a persistent digital identifier ensuring that it will be available in perpetuity.
Within the repository is documentation to reproduce each manuscript figure and each reported statistic.
The lab is a strong proponent of open science and has adhered to this lab policy for every published manuscript.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyslexia, Developmental
-
Georgia State UniversityMedical University of South Carolina; National Institutes of Health (NIH)CompletedDevelopmental Reading Disorder | Dyslexia, DevelopmentalUnited States
-
IRCCS Eugenio MedeaCompletedDevelopmental Dyslexia | Developmental Spelling DisorderItaly
-
University Hospital, ToulouseCompletedDevelopmental Dyslexia | Developmental Coordination DisorderFrance
-
Ahmet EmirCompletedIntellectual Disability | Developmental Dyslexia | Developmental DisabilityTurkey
-
Catholic University of the Sacred HeartFondazione Policlinico Universitario Agostino Gemelli IRCCS; Fondazione I.R...Enrolling by invitationDevelopmental DyslexiaItaly
-
University of ZurichUnknown
-
CNGE IRMG AssociationScalab CNRS 9193UnknownSpecific Learning Disorder | Developmental Coordination Disorder | Specific Developmental Disorders of Speech and Language | Dyslexia, Developmental | DyspraxiaFrance
-
Bambino Gesù Hospital and Research InstituteRecruitingDevelopmental DyslexiaItaly
-
Bambino Gesù Hospital and Research InstituteEnrolling by invitationDevelopmental DyslexiaItaly
-
Scalab CNRS 9193UnknownDevelopmental DyslexiaFrance
Clinical Trials on Lindamood-Bell Seeing Stars
-
Eunice Kennedy Shriver National Institute of Child...UnknownDevelopmental DyslexiaUnited States